SuperworthNephros profit margin NEPH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 8.4%
- Operating margin, 12 months
- 7.9%
- Net margin on a year earlier
- +0.4 pts
- Peer median
- 7.7%
Over the twelve months to Jun 30, 2026, Nephros kept 8.4% of its revenue as net profit, with an operating margin of 7.9% and a gross margin of 61.3%.
Five years earlier its net margin was −36.3%.
The median for 6 medical instruments and supplies stocks of a similar size is 7.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 6.4% | 6.1% | 61.9% |
| FY2024 | 0.5% | 0.0% | 61.6% |
| FY2022 | −74.0% | −43.5% | 47.3% |
| FY2021 | −38.7% | −35.5% | 55.3% |
| FY2020 | −52.9% | −49.9% | 57.4% |
| FY2019 | −30.8% | −30.5% | 58.9% |
| FY2018 | −59.8% | −53.0% | 56.3% |
| FY2017 | −21.2% | −58.4% | 60.2% |
| FY2016 | n/a | n/a | 55.8% |
| FY2015 | n/a | n/a | 54.5% |
| FY2014 | n/a | n/a | 68.6% |
| FY2013 | n/a | n/a | 48.3% |
| FY2012 | n/a | n/a | 59.2% |
| FY2011 | n/a | n/a | 39.2% |
| FY2010 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 8.4% | +0.4 pts | 7.9% | |
| Q1 FY26 | 4.1% | −1.1 pts | 3.5% | |
| Q4 FY25 | 6.4% | +5.8 pts | 6.1% | |
| Q3 FY25 | 8.3% | n/a | 8.1% | |
| Q2 FY25 | 8.0% | n/a | 8.0% | |
| Q1 FY25 | 5.2% | n/a | 5.0% | |
| Q4 FY24 | 0.5% | n/a | 0.0% | |
| Q3 FY24 | n/a | n/a | −7.1% | |
| Q2 FY24 | n/a | n/a | −9.9% | |
| Q1 FY24 | n/a | n/a | −10.6% | |
| Q3 FY23 | −13.6% | +61.1 pts | −12.1% | |
| Q2 FY23 | −40.0% | +13.9 pts | −22.2% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Nephros' size, closest first, today.
| Company | Profit margin |
|---|---|
| NEPHNephros | 8.4% |
| APTAlpha Pro Tech | 6.8% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| UTMDUtah Medical Products | 29.0% |
| INFUInfuSystem | 6.0% |
| EMBCEmbecta | 8.6% |
| Peer median | 7.7% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Nephros
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.